AC Immune

ACIU · Nasdaq · Switzerland

Share price · ACIU

$2.10-0.47 (-18.29%) 3M

close as of 2026-11-18 · 24h delayed · vol 80K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ACIU's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 1 Oct 2026+7.3%

    Nothing announced by ACIU that day or the session before.

  2. 21 Aug 2026+9.8%
  3. 11 Aug 2026+11.4%
  4. 30 Jun 2026-10.5%
  5. 28 May 2026-6.1%
  6. 28 Apr 2026+6.7%
  7. 7 Apr 2026+15.2%
  8. 18 Feb 2026-10.0%
  9. 11 Dec 2025+15.4%

Share of unusual movement by asset

For each asset, the share of ACIU's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—25%
Sessions with no dated event—75%

No dated announcements about its assets since 2 Jul 2024.

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
TauVaccine
Alzheimer's Disease
Phase 2
alpha-synucleinVaccine
Parkinson's Disease
Phase 1/2
Amyloid-betaVaccine
Alzheimer's Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ACI-35.030Phase 2Alzheimer Disease
Est. primary completion 2026-12-22 · NCT06544616 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
AFFITOPE PD01A / ACI-7104.056Phase 2Parkinson Disease, Parkinson Disease 6, Early-Onset
Est. primary completion 2028-06 · NCT06015841 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
ACI-24.060Phase 1/2Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Est. primary completion 2029-04 · NCT05462106 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$1.6M$20M$32M+ $128M short-term inv.$26Mreport ↗

AC Immune reported revenue of $1.59M for Q2 2025, up 109.2% YoY, with R&D spend of $20.39M, up 7.6% YoY. Cash and equivalents were $32.44M, and the company posted a net loss of $25.68M, equal to its quarterly net burn of $25.68M.

Management announced a strategic review leading to a workforce reduction of around 30% and extended cash resources, reported as CHF 127.1M as of June 30, 2025, expected to fund operations through the end of Q3 2027 excluding potential partnering payments. Guidance was maintained for previously announced timelines, with interim clinical data from ACI-7104.056 and ACI-24.060 expected in H2 2025 and H1 2026, respectively, while pipeline focus shifts to Phase 2 active immunotherapies and small molecule programs targeting NLRP3 and Tau.

View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q2$0.8M$19M$57M+ $137M short-term inv.$25Mreport ↗
2023-Q2$0$15M$45M+ $59M short-term inv.$19Mreport ↗
2022-Q3$4.1M$15M$45M$14M-$14M operating cash flowreport ↗
2022-Q2$0$16M$66M$20Mreport ↗
2021-Q3$0$16M$100M$17Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$4.3M$68M$34M+ $82M short-term inv.$21M-$84M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$31M$71M$40M+ $143M short-term inv.$14M$75M operating cash flowreport ↗
2023-FY$16M$61M$93M+ $29M short-term inv.$15M-$67M operating cash flowreport ↗
2022-FY$4.1M$63M$34M+ $98M short-term inv.$19M-$77M operating cash flowreport ↗
2021-FY$0$68M$90M+ $127M short-term inv.$20M-$72M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($31K), 2 sales ($59K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-11June Carl Howard · directorAward / grant16,568——Form 4
2026-06-11Buetler Monika · directorAward / grant17,751——Form 4
2026-06-11Zuegel Martin · director, Interim CEOAward / grant33,136——Form 4
2026-06-11AGUIAR-LUCANDER RENEE · directorAward / grant16,568——Form 4
2026-06-11Twyman Roy Ervin · directorAward / grant16,568——Form 4
2026-06-11June Carl Howard · directorAward / grant (derivative)38,889——Form 4
2026-06-11Buetler Monika · directorAward / grant (derivative)41,667——Form 4
2026-06-11Zuegel Martin · director, Interim CEOAward / grant (derivative)77,778——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 46 reporting institutions held 25.1M shares ($68.6M, 24.7% of shares outstanding).

#InstitutionSharesValue
1BVF INC/IL19,822,436$54.5M
2WELLS FARGO & COMPANY/MN1,004,284$2.8M
3MILLENNIUM MANAGEMENT LLC792,657$2.2M
4RENAISSANCE TECHNOLOGIES LLC624,367$1.7M
5BlackRock, Inc.524,278$1.4M
6ARROWSTREET CAPITAL, LIMITED PARTNERSHIP405,658$1.1M
7DIMENSIONAL FUND ADVISORS LP390,165$1.1M
8NORTHERN TRUST CORP278,513$766K
9CITADEL ADVISORS LLC267,233$735K
10MARSHALL WACE, LLP131,458$362K
11Dauntless Investment Group, LLC107,489$296K
12UBS Group AG101,629$279K
13SUSQUEHANNA INTERNATIONAL GROUP, LLP89,262$245K
14MORGAN STANLEY89,253$245K
15GEODE CAPITAL MANAGEMENT, LLC63,601$175K